We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$4.22B
AUM Growth
-$1.2B
Cap. Flow
-$1.32B
Cap. Flow %
-31.23%
Top 10 Hldgs %
40.53%
Holding
893
New
143
Increased
129
Reduced
82
Closed
273
Avg Time Held Equity + Options
3.6 quarters
Top 10 Avg Time Held Equity + Options
0.7 quarters
Top 20 Avg Time Held Equity + Options
0.8 quarters
Avg Time Held Equity only
3.7 quarters
Top 10 Avg Time Held Equity only
0.7 quarters
Top 20 Avg Time Held Equity only
0.8 quarters

Top Buys

Rank Stock Value
1
OSH
Oak Street Health, Inc.
OSH
+$211M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$189M
3
UNVR
Univar Solutions Inc.
UNVR
+$175M
4
MAXR
Maxar Technologies Inc. Common Stock
MAXR
+$143M
5
AQUA
Evoqua Water Technologies Corp. Common Stock
AQUA
+$137M

Top Sells

Rank Stock Value
1
STOR
STORE Capital Corporation
STOR
+$414M
2
LHCG
LHC Group LLC
LHCG
+$211M
3
ATVI
Activision Blizzard
ATVI
+$196M
4
SGFY
Signify Health, Inc.
SGFY
+$161M
5
ONEM
1Life Healthcare
ONEM
+$141M

Sector Composition

Rank Sector Weight
1 Financials 22.21%
2 Healthcare 21.3%
3 Technology 18.64%
4 Miscellaneous 15.12%
5 Industrials 5.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RDNW icon
401
RideNow Group
RDNW
$197M
$909K 0.02%
150,000
– –
2022 Q2
3 quarters
DCPH icon
402
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$907K 0.02%
58,695
+11,195
+24% +$187K
2022 Q3
2 quarters
LBPH icon
403
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$904K 0.02%
+230,000
New +$1.12M
2023 Q1
0 quarters
EWTX icon
404
Edgewise Therapeutics
EWTX
$4.18B
$887K 0.02%
132,968
-3,668
-3% -$34K
2022 Q2
3 quarters
ETNB icon
405
DELISTED
89bio
ETNB
$852K 0.02%
55,939
-53,351
-49% -$696K
2022 Q3
2 quarters
INZY icon
406
DELISTED
Inozyme Pharma
INZY
$846K 0.02%
147,654
+7,031
+5% +$18.6K
2022 Q2
3 quarters
NVNO icon
407
enVVeno Medical
NVNO
$5.66M
$840K 0.02%
5,075
+242
+5% +$45.2K
2022 Q1
4 quarters
BHAC icon
408
DELISTED
Focus Impact BH3 Acquisition Company Class A Common Stock
BHAC
$835K 0.02%
81,132
– –
2021 Q4
5 quarters
RZLT icon
409
Rezolute
RZLT
$471M
$827K 0.02%
+430,475
New +$969K
2023 Q1
0 quarters
OSI icon
410
DELISTED
Osiris Acquisition Corp.
OSI
$808K 0.02%
82,386
-153,004
-65% -$1.52M
2021 Q3
6 quarters
XRX icon
411
PUT
Xerox
XRX
$356M
$759K 0.02%
248,800
+206,100
+483% +$3.33M
2021 Q2
7 quarters
GLUE icon
412
Monte Rosa Therapeutics
GLUE
$897M
$744K 0.02%
95,528
+4,549
+5% +$31.6K
2022 Q1
4 quarters
RLAY icon
413
Relay Therapeutics
RLAY
$3.94B
$726K 0.02%
44,100
-12,900
-23% -$231K
2022 Q4
1 quarter
F icon
414
PUT
Ford
F
$47.9B
$721K 0.02%
771,200
+347,700
+82% +$4.35M
2022 Q2
3 quarters
PHAT icon
415
Phathom Pharmaceuticals
PHAT
$577M
$715K 0.02%
100,093
-54,000
-35% -$474K
2022 Q1
4 quarters
REPL icon
416
Replimune Group
REPL
$1.23B
$698K 0.02%
+39,500
New +$939K
2023 Q1
0 quarters
CRC icon
417
California Resources
CRC
$4.75B
$691K 0.02%
17,959
+223
+1% +$9.23K
2020 Q4
9 quarters
DTIL icon
418
Precision BioSciences
DTIL
$180M
$691K 0.02%
30,528
+4,620
+18% +$152K
2022 Q2
3 quarters
GEHC icon
419
GE HealthCare
GEHC
$30.6B
$689K 0.02%
8,400
-18,000
-68% -$1.29M
2022 Q4
1 quarter
PEN icon
420
Penumbra
PEN
$12.6B
$681K 0.02%
2,442
-8,134
-77% -$2.08M
2022 Q1
4 quarters
ACRS icon
421
Aclaris Therapeutics
ACRS
$530M
$677K 0.02%
83,678
-51,015
-38% -$647K
2022 Q1
4 quarters
BCAB icon
422
DELISTED
BIOATLA INC
BCAB
$657K 0.02%
4,901
+578
+13% +$104K
2022 Q3
2 quarters
BAX icon
423
Baxter International
BAX
$12.8B
$653K 0.02%
16,097
-36,633
-69% -$1.55M
2022 Q1
4 quarters
RVNC icon
424
DELISTED
Revance Therapeutics, Inc.
RVNC
$651K 0.02%
20,214
-69,061
-77% -$2.15M
2022 Q1
4 quarters
ANNX icon
425
Annexon
ANNX
$751M
$643K 0.02%
166,907
+7,948
+5% +$43.7K
2022 Q1
4 quarters
15 16
17
18 19

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q1 2023 Portfolio in Review

As of Q1 2023, UBS O'Connor held 893 positions worth $4.22B, down 22% from $5.42B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

UBS O'Connor withdrew a net $1.32B in Q1 2023, closing 273 positions and reducing 82 holdings. Its most notable exit was STORE Capital Corporation, an estimated $414M position sold in full.

By sector, the portfolio is most concentrated in Financials at 22% of assets, down from 26% a quarter earlier, followed by Healthcare and Technology.

Against the trend, UBS O'Connor opened a new position in Oak Street Health, Inc. worth $25.3M.

  • UBS O'Connor's largest Q1 2023 buy was Oak Street Health, Inc.: 6,537,297 shares worth $25.3M.
  • UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, an estimated $189M increase.
  • UBS O'Connor's biggest Q1 2023 reduction was Activision Blizzard, cutting an estimated $196M.
  • UBS O'Connor fully exited STORE Capital Corporation in Q1 2023, selling an estimated $414M.
  • UBS O'Connor's ten largest holdings make up 41% of its $4.22B portfolio in Q1 2023.
  • UBS O'Connor opened 143 new positions and closed 273 in Q1 2023.
  • UBS O'Connor's portfolio value fell 22% quarter-over-quarter to $4.22B.

Based on UBS O'Connor's 13F filing for Q1 2023, filed 15 May 2023.